Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant + onapristone
- Development stage
- Discontinued
- Lead developer
- Context Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fulvestrant + onapristone is an investigational combination therapy consisting of fulvestrant, an estrogen receptor antagonist, and onapristone, a progesterone receptor antagonist. This combination targets both hormone receptors in hormone receptor-positive breast cancer, with the goal of overcoming resistance to single-agent endocrine therapies. Onapristone is formulated as an extended-release version (ONA-XR) to reduce potential liver toxicity while maintaining efficacy.
- Other names
- onapristone extended release + fulvestrant
02
Targets
ER (Estrogen receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on fulvestrant + onapristone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant + onapristone.